2-(N-甲基苄基氨基)乙基 3-氨基丁-2-烯酸酯 | 54527-73-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(N-甲基苄基氨基)乙基 3-氨基丁-2-烯酸酯
• 中文别名: 尼卡地平中间体；2-(N-甲基苄基氨基)乙基3-氨基丁-2-烯酸酯
• 英文名称: 2-(N-benzil-N-methylamino)ethyl 3-aminocrotonate
• 英文别名: 2-(N-benzoyl-N-methylamino)ethyl 3-aminocrotonate；2-ethyl 3-aminocrotonate；N-benzyl-N-methylaminoethyl 3-aminocrotonate；2-[Benzyl(methyl)amino]ethyl 3-aminobut-2-enoate
• CAS: 54527-73-0
• 化学式: C₁₄H₂₀N₂O₂
• 分子量: 248.325
• InChiKey: UECDKJVOYBYWQP-UHFFFAOYSA-N

物化性质

• 熔点：
  59-61 °C
• 沸点：
  382.5±27.0 °C(Predicted)
• 密度：
  1.083±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  55.6
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险品标志：
  Xi,N
• 安全说明：
  S24,S37,S61
• 危险类别码：
  R51/53,R43
• 海关编码：
  2924299090

反应信息

• 作为反应物：
  描述：

  2-(N-甲基苄基氨基)乙基 3-氨基丁-2-烯酸酯 在 三乙胺 、 三氯氧磷 作用下， 以 甲醇 为溶剂， 反应 23.5h， 生成 2-Chloro-6-methyl-4-(3-nitro-phenyl)-1,4-dihydro-pyridine-3,5-dicarboxylic acid 5-[2-(benzyl-methyl-amino)-ethyl] ester 3-methyl ester
  参考文献：
  名称：

  通过用氧氯化磷氯化2-羟基-1,4-二氢吡啶来合成新型2-氯-1,4-二氢吡啶。

  摘要：

  通过用POCl3氯化2-羟基-1,4-二氢吡啶合成了新型2-氯-1,4-二氢吡啶衍生物。与在位置2具有甲基的二氢吡啶（尼卡地平和尼群地平）相比，在位置2氯化的二氢吡啶具有更强的血管舒张和降压活性。

  DOI：

  10.1248/cpb.37.2117
• 作为产物：
  描述：

  2-(苄基甲基氨基)乙基乙酰乙酸酯 在 氨 作用下， 以 甲醇 为溶剂， 生成 2-(N-甲基苄基氨基)乙基 3-氨基丁-2-烯酸酯
  参考文献：
  名称：

  Synthesis of new water-soluble dihydropyridine vasodilators.

  摘要：

  制备了几种水溶性二氢吡啶血管扩张剂，并评估了它们的血管扩张活性。其中，2-（N-苯基-N-甲基氨基）-乙基-甲基-2, 6-二甲基-4-（m-硝基苯基）-1, 4-二氢吡啶-3, 5-二羧酸盐盐酸盐（YC-93）被发现具有出色的活性和生物利用度。对该化合物的各种合成路线进行了研究。

  DOI：

  10.1248/cpb.27.1426

文献信息

• Synthesis of 1,4-Dihydropyridine-5-phosphonates and Their Calcium-Antagonistic and Antihypertensive Activities. Novel Calcium-Antagonist 2-(Benzyl(phenly)amino)ethyl 5-(5,5-Dimethyl-2-oxo-1,3,2-dioxaphosphorinan-2-yl)-1,4-dihydro-2,6-dimethyl-4-(3-nitrophenyl)-3-pyridinecarboxylate Hydrochloride Ethanol(NZ-105) and Its Crystal Structure.
  作者：Ryozo SAKODA、Yoshimasa KAMIKAWAJI、Kiyotomo SETO

  DOI：10.1248/cpb.40.2362

  日期：——

  The effect of the 3-carboxylic-ester variation in 2, 2-dimethyltrimethylene 3-alkoxycarbonyl-4-aryl-1, 4-dihydro-2, 6-dimethyl-5-pyridinephosphonates (1) was investigated with relation to the calcium-antagonistic and antihypertensive activities : the analogs contaning the alkyl groups of not more than 12 carbons and an amino functionality in the carboxylic-ester moiety were synthesized to be examined for biological activities. Among them, 2-[benzyl(phenyl)amino]-ethyl 5(5, 5-dimethyl-2-oxo-1, 3, 2-dioxaphosphorinan-2-yl)-1, 4-dihydro-2, 6-dimethyl-4-(3-nitrophenyl)-3-phridine-carboxylate hydrochloride ethanol (NZ-105) showed particularly beneficial activities and was selected for further pharmacological studies and clinical development. Some aspects of the structure-activity relationships and solid-state structure of NZ-105 by X-ray crystallographic analysis were described.

  研究了3-羧酸酯变体在2,2-二甲基三甲基烯-3-烷氧羰基-4-芳基-1,4-二氢-2,6-二甲基-5-吡啶膦酸酯(1)中与钙拮抗和降压活性相关的影响：合成了含有不超过12个碳的烷基和羧酸酯部分含有氨基功能团的类似物，以检测其生物活性。其中，2-[苄基(苯基)氨基]乙基5-(5,5-二甲基-2-氧-1,3,2-二氧膦杂环己烷-2-基)-1,4-二氢-2,6-二甲基-4-(3-硝基苯基)-3-吡啶羧酸酯盐酸盐乙醇(NZ-105)显示出特别有益的活性，并被选中进行进一步的药理学研究和临床开发。描述了通过X射线晶体学分析获得的NZ-105的结构-活性关系和固态结构的一些方面。
• Synthesis and antihypertensive activities of 1,4-dihydropyridine-5-phosphonate derivatives. I.
  作者：IWAO MORITA、SHIN-ICHI TADA、KATSUTOSHI KUNIMOTO、MASAMI TSUDA、MASAHIRO KISE、KIYOSHI KIMURA

  DOI：10.1248/cpb.35.3898

  日期：——

  A series of phosphonate derivatives, designed as analogues of 1, 4-dihydropyridine-3, 5- dicarboxylates in which a phosphonate group was introduced instead of the carboxylate group at the 5-position, was synthesized, and their antihypertensive activities were examined. Among the compounds examined, 5-diallyloxyphosphinyl-1, 4-dihydropyridine-3-carboxylates were most effective in lowering the blood pressure in normotensive rats and spontaneously hypertensive rats (SHR). The phosphonate derivatives are considered to be close analogues of the carboxylate derivatives. The structure-activity relationships are discussed.

  一系列膦酸盐衍生物被设计为1,4-二氢吡啶-3,5-二羧酸盐的类似物，其中在5-位引入了膦酸基团而非羧酸基团，这些化合物被合成并检测了它们的降血压活性。在所研究的化合物中，5-二烯丙氧基膦基-1,4-二氢吡啶-3-羧酸盐在降低正常血压大鼠和自发性高血压大鼠（SHR）的血压方面最为有效。这些膦酸盐衍生物被认为是羧酸盐衍生物的近似类似物。结构-活性关系在此进行了讨论。
• Synthesis and antihypertensive activities of 1,4-dihydropyridine-5-phosphonate derivatives. II.
  作者：IWAO MORITA、KATSUTOSHI KUNIMOTO、MASAMI TSUDA、SHIN-ICHI TADA、MASAHIRO KISE、KIYOSHI KIMURA

  DOI：10.1248/cpb.35.4144

  日期：——

  A series of 1, 4-dihydropyridine-5-cyclic phosphonate derivatives, designed as analogues of 1, 4- dihydropyridine-3, 5-dicarboxylate calcium antagonists, was synthesized and examined for antihypertensive activity. Several compounds were proved to have activities superior or comparable to that of nifedipine in lowering blood pressure in normotensive and spontaneously hypertensive rats (SHR). Among these compounds, methyl 2, 6-dimethyl-5- (2-oxo-1, 3, 2-dioxaphosphorinan-2-yl) -4- (2-nitrophenyl) -1, 4-dihydropyridine-3-carboxylate (31, DHP-218) was approximately 7 times more active than nifedipine in SHR and was selected for further development and clinical evaluation. The structure-activity relationships are discussed.

  合成了一系列1,4-二氢吡啶-5-环状磷酸酯衍生物，作为1,4-二氢吡啶-3,5-二羧酸钙拮抗剂的类似物，并对其抗高血压活性进行了检查。几种化合物在降低正常血压和自发性高血压大鼠（SHR）的血压方面被证明具有优于或可比于硝苯地平的活性。在这些化合物中，甲基2,6-二甲基-5-(2-氧-1,3,2-二氧磷烷-2-基)-4-(2-硝基苯基)-1,4-二氢吡啶-3-羧酸酯（31，DHP-218）在SHR中的活性约为硝苯地平的7倍，并被选为进一步开发和临床评估的候选化合物。讨论了结构-活性关系。
• 1,4-Dihydropyridine derivatives
  申请人：Korea Research Institute of Chemical Technology

  公开号：EP0324626A1

  公开（公告）日：1989-07-19

  1,4-dihydropyridine derivatives represented by the formula: wherein R¹ and R², different from the other, is selected from the group consisting of lower alkyl, lower alkenyl, lower alkoxyalkyl or aminoaryl(lower)alkyl having carbon atoms of 1 to 6, which may be substituted or unsubstituted by a lower alkyl having carbon atoms of 1 to 4, wherein at least one of R¹ and R² is a lower alkenyl having carbon atoms of 3 to 6 whose 1- or 2- position is substituted by a lower alkyl having carbon atoms of 1 to 4; and R³ is a nitro group in ortho-, meta- or para-position of the phenyl. The compounds are useful as vasodilators and in the treatment of hypertension.

  1,4-二氢吡啶衍生物的化学式表示为：其中R¹和R²，不同于另一个，选自由1至6个碳原子的较低烷基、较低烯基、较低烷氧基烷基或氨基芳基(较低)烷基组成的基团，该基团可能被1至4个碳原子的较低烷基取代或未取代，其中R¹和R²中至少一个是碳原子为3至6的较低烯基，其1-或2-位置被1至4个碳原子的较低烷基取代；以及R³是苯环的邻位、间位或对位的硝基基团。这些化合物可用作扩血管剂，并用于治疗高血压。
• Processes of manufacturing substituted-1,4-dihydropyridines, improved aqueous solutions thereof, and processes of manufacturing the solutions
  申请人：Jobdevairakkam Christopher N.

  公开号：US20080125595A1

  公开（公告）日：2008-05-29

  A process of preparing a stable parenteral solution of a 1,4-dihydropyridine salt, such as nicardipine hydrochloride, in an acidic aqueous medium. The presence of L-arginine in the solution enhances the solubility of the salt, which is poorly soluble in water. An aqueous, injectable isotonic solution at pH about 3.5-3.6 consists essentially of nicardipine hydrochloride, L-arginine, and a sugar alcohol. An improved single pot manufacturing process for obtaining unsymmetrical 1,4-dihydropyridines by using more than one mole equivalent of aldehyde with respect to the other reactants (amino crotonate and acetoacetate ester). The reaction can be conducted in a solvent present at 20 times the amount of any one component. A process for changing one polymorph of nicardipine hydrochloride (Form A) into another (Form B), and a separate process for the reverse (Form B into Form A).

  一种制备1,4-二氢吡啶盐（如盐酸尼卡地平）的稳定无菌溶液的工艺，该工艺在酸性水介质中进行。溶液中存在L-精氨酸，可增强盐的溶解度，而盐在水中溶解度较差。该无菌溶液为水溶性、注射用的等渗溶液，pH值约为3.5-3.6，主要由盐酸尼卡地平、L-精氨酸和糖醇组成。 一种改进的单锅制造工艺，用于通过使用超过其他反应物（氨基丙烯酸酯和乙酰乙酸酯）的摩尔当量的醛类来获得非对称的1,4-二氢吡啶。该反应可以在溶剂中进行，溶剂的量为任何一个组分的20倍。 一种将尼卡地平盐酸的一种多晶形式（A型）转变为另一种多晶形式（B型）的工艺，以及将B型转变为A型的单独工艺。